These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7112514)

  • 1. Distinction of two pathologic antithrombin III molecules: antithrombin III "Aalborg' and antithrombin III "Budapest'.
    Sørensen PJ; Sas G; Petó I; Blaskó G; Kremmer T; Samu A
    Thromb Res; 1982 May; 26(3):211-9. PubMed ID: 7112514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal properties and behaviors of antithrombin III found in a thrombophilic patient: defective biological functions and dissimilar antigenic determinants.
    Murayama H; Matsuda M
    Thromb Haemost; 1986 Oct; 56(2):165-71. PubMed ID: 3101219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville.
    Aiach M; Nora M; Fiessinger JN; Roncato M; François D; Gelas MA
    Thromb Res; 1985 Sep; 39(5):559-70. PubMed ID: 4082101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III.
    Cerskus AL; Birchall KJ; Ofosu FA; Hirsh J; Blajchman MA
    Can J Biochem Cell Biol; 1984 Oct; 62(10):975-83. PubMed ID: 6509363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and characterisation of the pathological antithrombin III "Aalborg".
    Sørensen PJ; Ezban M; Jessen TE; Sas G; Blasko G; Jørgensen M
    Thromb Res; 1990 Mar; 57(5):807-12. PubMed ID: 2339371
    [No Abstract]   [Full Text] [Related]  

  • 8. Homozygous variant of antithrombin III: AT III Fontainebleau.
    Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
    Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy.
    Aiach M; François D; Priollet P; Capron L; Roncato M; Alhenc-Gelas M; Fiessinger JN
    Br J Haematol; 1987 Aug; 66(4):515-22. PubMed ID: 3663508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of the "classical" antithrombin III deficiency.
    Sas G; Petö I; Bánhegyi D; Blaskó G; Domján G
    Thromb Haemost; 1980 Jun; 43(2):133-6. PubMed ID: 7455972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.
    Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K
    Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification of antithrombin 'Vicenza': a molecule with normal heparin affinity and impaired reactivity to thrombin.
    Finazzi G; Tran TH; Barbui T; Duckert F
    Br J Haematol; 1985 Feb; 59(2):259-63. PubMed ID: 3970857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest.
    Sas G; Pepper DS; Cash JD
    Thromb Diath Haemorrh; 1975 Jun; 33(3):564-72. PubMed ID: 1154312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
    Lane DA; Denton J; Flynn AM; Thunberg L; Lindahl U
    Biochem J; 1984 Mar; 218(3):725-32. PubMed ID: 6721831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the biological activity of antithrombin III in patients with hepatic cirrhosis.
    Matsuo T; Matsuo C; Matsuo O
    Clin Chim Acta; 1984 Jul; 140(2):125-32. PubMed ID: 6467606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients.
    Fischer AM; Dautzenberg MD; Aurousseau MH; Béguin S; Goudemand J; Hemker HC
    Thromb Res; 1985 Jan; 37(2):295-307. PubMed ID: 2579452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.